There are many ways to modulate the immune response in a therapeutic setting. Drugs that target the proinflammatory mediator IL-1, for instance, can counteract disease in certain types of inflammatory conditions. But such drugs do not work well for other conditions, such as rheumatoid arthritis and other autoimmune diseases. New clinical studies, examined by Kingston Mills and Aisling Dunne, provide insight into this discrepancy. Another approach that has worked well in mice harnesses the ability of regulatory T cells to dampen the immune response. But one barrier in the way of successful application to people is the ability of such cells to change their character for the worse. Massimo Gadina and John O'Shea take a look at a basic research study that highlights this dilemma and examine what it means for the future of human trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CLEC5A is a critical receptor in innate immunity against Listeria infection
Nature Communications Open Access 21 August 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dinarello, C.A. Annu. Rev. Immunol. 27, 519–550 (2009).
Masters, S.L., Simon, A., Aksentijevich, I. & Kastner, D.L. Annu. Rev. Immunol. 27, 621–668 (2009).
Aksentijevich, I. et al. N. Engl. J. Med. 360, 2426–2437 (2009).
Reddy, S. et al. N. Engl. J. Med. 360, 2438–2444 (2009).
Geddes, K., Magalhaes, J.G. & Girardin, S.E. Nat. Rev. Drug Discov. 8, 465–479 (2009).
Martinon, F., Burns, K. & Tschopp, J. Mol. Cell 10, 417–426 (2002).
Sutton, C., Brereton, C., Keogh, B., Mills, K.H. & Lavelle, E.C. J. Exp. Med. 203, 1685–1691 (2006).
Mills, K.H. Eur. J. Immunol. 38, 2636–2649 (2008).
Sutton, C.E. et al. Immunity 31, 331–341 (2009).
Brydges, S.D. et al. Immunity 30, 875–887 (2009).
Meng, G., Zhang, F., Fuss, I., Kitani, A. & Strober, W. Immunity 30, 860–874 (2009).
Bianchi, M.E. J. Leukoc. Biol. 81, 1–5 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.H.G.M. is a cofounder, minority shareholder, consultant, and scientific advisory board member of Opsona Therapeutics, Ltd.
Rights and permissions
About this article
Cite this article
Mills, K., Dunne, A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med 15, 1363–1364 (2009). https://doi.org/10.1038/nm1209-1363
Issue Date:
DOI: https://doi.org/10.1038/nm1209-1363
This article is cited by
-
T cell subsets: an integral component in pathogenesis of rheumatic heart disease
Immunologic Research (2018)
-
CLEC5A is a critical receptor in innate immunity against Listeria infection
Nature Communications (2017)
-
RETRACTED ARTICLE: Variant Interleukin-1 Receptor-Associated Kinase-2 Mediates Increased NF-κB and p38 Activity Induced by Lipopolysaccharide
Inflammation (2014)
-
A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis
Journal of Investigative Dermatology (2013)